UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 24, 2018

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)

California
(State or Other Jurisdiction of Incorporation)

333-198073	**02-0692322**
(Commission File Number)	(IRS Employer Identification No.)

12744 San Fernando Road, Suite 400
Sylmar, California 91342
(Address of Principal Executive Offices)

(818) 833-5000
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. **REGULATION FD DISCLOSURE**

A copy of a slide presentation entitled “Enriching the Lives of the Blind” that Second Sight Medical Products, Inc. ("Second Sight ") will use during presentations made before individuals and small groups at the 19th Annual B. Riley FBR Institutional Investor Conference, on May 24, 2018 (the "Presentation Materials"), is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, Second Sight has posted the Presentation Materials on the Investor Relations section of Second Sight's website: http://investors.secondsight.com. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit No. Description

99.1 Second Sight Medical Products, Inc. Investor Presentation entitled “Enriching the Lives of the Blind” dated May 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 24, 2018

SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ John T. Blake
By: John T. Blake
Chief Financial Officer

Exhibit 99.1

Enriching the Lives of the Blind

May 2018

Forward Looking Statements

NASDAQ: EYES

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on March 20, 2018, and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

Two Breakthrough Technologies

NASDAQ: EYES

Argus® II
retinal prosthesis

- First and only FDA approved retinal prosthesis
- 20+ years and ~$200 million invested to develop and commercialize
- Established technology with 276+ implants
- Approved for individuals with retinitis pigmentosa (bare-light and no-light perception in U.S.)





Orion ™ I
visual cortical prosthesis

- Leveraging Argus II technology
- Bypasses the retina and optic nerve to directly stimulate the brain
- Transformational technology with human trial initiated Q1 2018
- Broad label potential including:
  - Glaucoma, diabetic retinopathy, or forms of cancer and trauma



Second Sight

Argus® II: Effective Treatment for Blindness

NASDAQ: EYES

Argus II is a retinal prosthesis that induces visual perception in individuals with severe to profound retinitis pigmentosa (RP)

Orion I: Breakthrough Device

NASDAQ: EYES

Leveraging Argus II technology, our breakthrough Orion platform bypasses the damaged eye and/or optic nerve to directly stimulate the brain

- Orion has the potential to treat many forms of blindness including glaucoma, diabetic retinopathy, forms of cancer and trauma
- Received FDA Breakthrough Device designation
  - Completed initial FDA submission in 2018
  - Requested FDA meeting to discuss regulatory and clinical path forward
- Conducting a five subject feasibility study at **UCLA Medical Center** and the **Baylor College of Medicine** in Houston
  - First two human subjects implanted and activated*; phase 2 spatial mapping underway
  - Four of five subjects implanted with fifth planned for Q2 2018
  - No serious adverse events reported

Poised for Growth

NASDAQ: EYES

Technology and commercial leadership positions us for growth



20 years Technology innovation	+	5+ years Commercial execution	=	Foundation for growth

Commercial Experience and Leverage

NASDAQ: EYES



Effective patient screening and rehabilitation workflows

High degree of patient qualification, best practices development, and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes

Scalable commercial infrastructure

Centers of Excellence, market access experience and leadership, channel with retinal surgeons—Infrastructure supports Orion commercialization

Market development

Established and growing new ophthalmology therapy in 14 markets worldwide, including the U.S., Canada, Europe, and Middle East

Argus II technology platform

Established technology with 10 years+ experience implant durability
Proprietary algorithms for artificial vision, leverage into Orion

Second Sight

Identifying and Recruiting Qualified Patients

NASDAQ: EYES

Second Sight

* As of May 10, 2018

2018 Key Drivers of Shareholder Value

NASDAQ: EYES



Second Sight

Select Financial Data

NASDAQ: EYES

(USD $ in thousands)	Q1 2018	FY 2017	FY 2016
Implants	***16***	***75 (30 in Q4)***	***42 (7 in Q4)***
Revenue	$976	$7,964	$3,985
Gross Profit (Loss)	$308	$2,847	$(6,091)
Net Loss	$(9,753)	$(28,516)	$(33,179)
Non-GAAP Adjusted Net Loss[1]	$(8,512)	$(27,576)	$(24,812)

Select projected financials at scale

Annual breakeven

>400 Units

Gross margins

+70%

(USD $ in thousands)	March 31, 2018	December 31, 2017
Cash and cash equivalents	$5,014	$7,839
Raised $10 million in private placement in May 2018		
Debt	$0	$0

1) Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory.

Second Sight Investment Highlights

NASDAQ: EYES

- **Technology Innovator with two platforms**
  - **Argus II retinal prosthesis**
    - First and only FDA approved retinal prosthesis; 5+ year first mover advantage in the U.S.
    - 20 years and ~$200 million invested in established technology
  - **Orion I visual cortical prosthesis system**
    - Leveraging Argus II technology to directly stimulate the brain
    - Human trial initiated Q1 2018
- **Large & Expanding Addressable Market**
  - Argus II: Currently RP with bare-light or no-light perception in U.S.
  - Argus II Better Vision: 3-5x current addressable market
  - Orion I: Nearly all forms of blindness including glaucoma, diabetic retinopathy, or forms of cancer and trauma
- **Established Argus II Reimbursement**
  - Currently the ONLY reimbursed retinal prosthesis treating blindness in U.S.
  - Reimbursement or funding in Canada, Germany, Italy, France and England
- **R&D Pipeline Expanding Market Potential**
  - Next generation Argus II externals and advanced stimulation programs in development
  - Submitted HDE supplement to the FDA during 2018 to expand Argus II label
  - Four of five patients implanted with the Orion in 1H 2018

Contacts

NASDAQ: EYES

Second Sight Medical Products, Inc.
12744 San Fernando Road
Suite 400
Sylmar, CA 91342
Main: 818-833-5000
www.secondsight.com

Will McGuire
President & CEO
Direct: 818-833-5040
wmcguire@secondsight.com

Retail Investor Relations
Greg Falesnik
Managing Director
MZ North America
Direct: 949-385-6449
Greg.Falesnik@mzgroup.us

Institutional Investor Relations
Lisa Wilson
President
In-Site Communications, Inc.
Direct: 212-452-2793
lwilson@insitecony.com